TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|Treatment-Refractory Solid Tumors|Retinoblastoma Deficiency|SCLC|Soft Tissue Sarcoma|Endometrial Cancer|Bladder Cancer
Interventions: DRUG: Palbociclib Oral Product|DRUG: TAS-116|DRUG: TAS-116|DRUG: TAS-116
Sponsor: Brown University